Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 413

1.

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.

Clegg LE, Heerspink HJL, Penland RC, Tang W, Boulton DW, Bachina S, Fox RD, Fenici P, Thuresson M, Mentz RJ, Hernandez AF, Holman RR.

Diabetes Care. 2018 Dec 6. pii: dc181871. doi: 10.2337/dc18-1871. [Epub ahead of print]

PMID:
30523029
2.

Simultaneous quantitation of metformin and dapagliflozin in human plasma by LC-MS/MS: Application to a pharmacokinetic study.

Shah PA, Shrivastav PS, Shah JV, George A.

Biomed Chromatogr. 2018 Dec 5:e4453. doi: 10.1002/bmc.4453. [Epub ahead of print]

PMID:
30517974
3.

The impact of dapagliflozin on glucose excursions related to early proatherogenic derangement in the aortic wall.

Stelmaszyk A, Wesołowska A, Pomieczyńska K, Iskakova S, Frydrychowicz M, Dworacki G, Dworacka M.

Saudi Pharm J. 2018 Dec;26(8):1192-1198. doi: 10.1016/j.jsps.2018.07.008. Epub 2018 Jul 20.

4.

Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.

Handelsman Y, Mathieu C, Del Prato S, Johnsson E, Kurlyandskaya R, Iqbal N, Garcia-Sanchez R, Rosenstock J.

Diabetes Obes Metab. 2018 Nov 30. doi: 10.1111/dom.13594. [Epub ahead of print]

PMID:
30499237
5.

Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Combination with Insulin in Japanese Patients with Type 1 Diabetes.

Watada H, Shiramoto M, Ueda S, Tang W, Asano M, Thoren F, Kim H, Yajima T, Boulton DW, Araki E.

Diabetes Obes Metab. 2018 Nov 30. doi: 10.1111/dom.13593. [Epub ahead of print]

PMID:
30499157
6.

Dapagliflozin DECLAREd safe.

Lim GB.

Nat Rev Cardiol. 2019 Jan;16(1):4. doi: 10.1038/s41569-018-0131-8. No abstract available.

PMID:
30479387
7.

Urinary glucose excretion after dapagliflozin treatment: an exposure-response modeling comparison between Japanese and non-Japanese patients diagnosed with Type 1 Diabetes Mellitus.

Sokolov V, Yakovleva T, Ueda S, Parkinson J, Boulton DW, Penland RC, Tang W.

Diabetes Obes Metab. 2018 Nov 19. doi: 10.1111/dom.13586. [Epub ahead of print]

PMID:
30456904
8.

A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.

Durak A, Olgar Y, Degirmenci S, Akkus E, Tuncay E, Turan B.

Cardiovasc Diabetol. 2018 Nov 17;17(1):144. doi: 10.1186/s12933-018-0790-0.

10.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators.

N Engl J Med. 2018 Nov 10. doi: 10.1056/NEJMoa1812389. [Epub ahead of print]

PMID:
30415602
11.

Reduction in Albuminuria With Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers.

Heerspink HJL, Sjöström CD, Inzucchi SE, Hallow MK, Cain VA, Rossing P, Stefansson BV, Sartipy P.

Diabetes Obes Metab. 2018 Nov 9. doi: 10.1111/dom.13579. [Epub ahead of print]

PMID:
30414240
12.

Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation.

Ye Y, Jia X, Bajaj M, Birnbaum Y.

Cardiovasc Drugs Ther. 2018 Dec;32(6):553-558. doi: 10.1007/s10557-018-6837-3.

PMID:
30367338
13.

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.

Dandona P, Mathieu C, Phillip M, Hansen L, Tschöpe D, Thorén F, Xu J, Langkilde AM; DEPICT-1 Investigators.

Diabetes Care. 2018 Dec;41(12):2552-2559. doi: 10.2337/dc18-1087. Epub 2018 Oct 23.

PMID:
30352894
14.

Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial.

Cho KY, Nakamura A, Omori K, Takase T, Miya A, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H.

Diabetes Obes Metab. 2018 Oct 12. doi: 10.1111/dom.13557. [Epub ahead of print]

PMID:
30311367
15.

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.

Rosenstock J, Mathieu C, Chen H, Garcia-Sanchez R, Saraiva GL.

Arch Endocrinol Metab. 2018 Aug;62(4):424-430. doi: 10.20945/2359-3997000000056.

16.

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.

Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T, Hirata KI.

Cardiovasc Diabetol. 2018 Oct 8;17(1):132. doi: 10.1186/s12933-018-0775-z.

17.

Early administration of dapagliflozin preserves pancreatic β-cell mass through a legacy effect in a mouse model of type 2 diabetes.

Kanno A, Asahara SI, Kawamura M, Furubayashi A, Tsuchiya S, Suzuki E, Takai T, Koyanagi-Kimura M, Matsuda T, Okada Y, Ogawa W, Kido Y.

J Diabetes Investig. 2018 Oct 5. doi: 10.1111/jdi.12945. [Epub ahead of print]

18.

Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study.

Abdul-Ghani M, Migahid O, Megahed A, Singh R, Fawaz M, DeFronzo RA, Jayyousi A.

Diabetes Obes Metab. 2018 Sep 26. doi: 10.1111/dom.13546. [Epub ahead of print]

PMID:
30259621
19.

Use of dapagliflozin in patients with advanced diabetic kidney disease.

Park HS, Jung YJ, Lee DY, Moon KH, Kim B, Kim HW.

Kidney Res Clin Pract. 2018 Sep;37(3):292-297. doi: 10.23876/j.krcp.2018.37.3.292. Epub 2018 Sep 30.

20.

Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease.

Choi DH, Jung CH, Mok JO, Kim CH, Kang SK, Kim BY.

Endocrinol Metab (Seoul). 2018 Sep;33(3):387-394. doi: 10.3803/EnM.2018.33.3.387.

Supplemental Content

Loading ...
Support Center